The Medicare program is taking steps to make it easier for low-income Americans to sign up for Medicare-approved prescription drug discount cards. Medicare will allow some states to sign up low-income seniors automatically and provide a standard ap
New York State Health Commissioner Antonia C. Novello, M.D., M.P.H., Dr.P.H., has announced the New York State Department of Health has begun distribution of its current supply of flu vaccine t
VaxGen announced today that the U.S. government has awarded the company an $877.5 million contract to supply 75 million doses of anthrax vaccine for civilian defense. The contract, the first of
Researchers from Kaiser Permanente's Northern California region are presenting a study at this week's American Heart Association Scientific Sessions showing that patients who use a generic st
During the current flu vaccine shortage, the Centers for Disease Control and Prevention, Department of Health and Human Services, has issued guidance recommending the use of certain alternative antiviral medications. Those unable to secure the
A breast cancer drug made by Pfizer Inc. increased survival rates by 63 percent compared with the standard therapy tamoxifen, researchers said on Wednesday.The clinical trial strengthens the case
An "old" drug has unique benefits for patients with acute myocardial infarction (AMI; commonly known as heart attack), a finding that may contribute to a new understanding of how heart attacks develop, according to an article in the September/October
Pennsylvania Department of Health Secretary Dr. Calvin B. Johnson today announced that the Department of Health will distribute about 340,000 doses of influenza vaccine that the Centers for Dis
Shire Pharmaceuticals Group has announced that Dementia patients receiving long-term treatment with Reminyl (more than 36 months) may be able to stay at home for longer compared to those receiving treat
HHS Secretary Tommy G. Thompson has announced that the Food and Drug Administration authorized the use of GlaxoSmithKline influenza vaccine, Fluarix, in the United States under an Investigational New Drug
"These results suggest that higher daily doses of CONCERTA may have greater therapeutic benefits in managing symptoms of children with ADHD that are not attained with lower doses of CONCERTA or with immediate release methylphenidate (IR MPH)," said study investigator George J. Wan, PhD, MPH, Director, Medical Affairs, McNeil Consumer & Specialty Pharmaceuticals. "Overall, CONCERTA was associated with clinically meaningful treatment response in approximately 70 percent of subjects. Higher doses of CONCERTA [36-54 mg once daily] produced significantly greater symptom response and remission rates," he added. The findings were presented at the New Clinical Drug Evaluation Unit meeting, a scientific conference sponsored by the National Institute of Mental Health.
About the Study A total of 282 children with ADHD, ages 6-12, participated in this randomized, multi-center, double-blind, placebo-controlled 28-day trial. Prior to randomization, subjects were assigned to dose levels based either on titration or conversion from previous MPH treatment. At 7:30 a.m., all children received CONCERTA (at either 18-, 36- or 54-mg) or IR MPH (5, 10, or 15 mg for a total daily dose of 15, 30, or 45 mg, respectively) or their corresponding matched placebos. At 11:30 a.m. and 3:30 p.m. children in the IR MPH group received the appropriate additional doses of IR MPH, whereas all others received placebo.
Response to therapy was measured by parent-rated IOWA Conners Inattention/ Overactivity (I/O) subscale. A clinically meaningful response to treatment was considered a >30% reduction from baseline IOWA Conners I/O score. Response rates were 69.2% for CONCERTA, 61.1% for IR MPH, and 21.4% for placebo (P < .0001; overall treatment comparison). These rates were 83.6% and 40% for CONCERTA dosages 36-54 mg (n=63) and 18 mg (n=31), respectively (P = .0001).
Subjects were considered to have achieved remission (no or minimal ADHD symptoms) when scores were reduced by >50%. Remission rates were 50.5% for CONCERTA, 36.7% for IR MPH, and 11.9% for placebo (P < .0001; overall treatment comparison). These rates were 62.3% and 26.7% for CONCERTA dosages 36-54 mg and 18 mg, respectively (P = .0018). No significant differences in response and remission rates were observed for IR MPH by dosage.